Cash shortage hurts Mich. biotech, drug-discovery firms

02/5/2009 | Ann Arbor Business Review (Mich.)

Dwindling support from venture capitalists and other funding sources in Michigan is slowing the growth of drug-discovery companies and forcing some biotech businesses to turn further to offering services, industry observers said. David Canter, who used to head Pfizer's operation in Ann Arbor, Mich., said discovery firms could benefit from increased activity in pharmaceutical services, and the state should keep on being an "idea factory" for the life sciences sector.

View Full Article in:

Ann Arbor Business Review (Mich.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN